Pietro Antonio Tataranni

Dr. Tataranni is the global Chief Medical Officer of PepsiCo. PepsiCo products are enjoyed by consumers more than one billion times a day in more than 200 countries and territories around the world, and generated more than $67 billion in net revenue in 2019, driven by a complementary food and beverage portfolio that includes Frito-Lay, Gatorade, Pepsi-Cola, Quaker and Tropicana. PepsiCo's product portfolio includes 23 brands that generate more than $1 billion each in estimated annual retail sales.

As Chief Medical Officer, Dr. Tataranni oversees all aspects of the company's efforts to protect its global workforce, products and communities in the face of the COVID-19 pandemic. He also leads PepsiCo's Life Sciences strategy and the R&D Fellows Program as its Executive Sponsor. Dr. Tataranni joined PepsiCo in September 2018 as the Senior Vice President of R&D Life Sciences, responsible for leading the development and execution of a nutrition and bio-sciences strategy in support of the company’s portfolio transformation and Winning with Purpose agenda.

Prior to joining PepsiCo, Dr. Tataranni was Senior Vice President, Head of Global Medical Affairs, Diabetes & Cardiovascular Business Unit, in charge of medical strategy worldwide and operations for mature markets at Sanofi. Previous responsibilities within the group included the roles of Vice President Global Medical Affairs, Medical Director Europe, Vice President for the Metabolism Medical Unit in the US affiliate (2006-2008) and Medical Director for the Metabolism Franchise (2005-2006). Between 1999 and 2004 he was Head of the Obesity, Diabetes and Energy Metabolism Unit at the Phoenix Epidemiology and Clinical Research Branch of the National Institutes of Health in the U.S. and Director of the Clinical Research Center at the same institution from 2000 through 2004.

Dr. Tataranni is an avid researcher who has published and lectured extensively at national and international meetings on obesity, diabetes and their cardio metabolic complications. Professional awards presented to Dr. Tataranni include the NIH Fellowship Award for Research Excellence (FARE) in 1998 and the North American Association for the Study of Obesity (NAASO)-Lilly Scientific Achievement Award in 2004.

Dr. Tataranni is a native of Italy. He graduated from Catholic University School of Medicine in Rome in 1990 and went on to receive a specialty diploma in Endocrinology, Metabolic Diseases and Diabetes at this University. He has authored more than 100 original manuscripts, in addition to contributing to numerous review articles and book chapters.